Sensitivity of anterior pituitary hormones to irradiation.
Cranial irradiation is used in the management of a diverse group of intracranial pathologies. However, if any part of the hypothalamic-pituitary axis is included in the radiation field, there is a risk of developing neuroendocrine dysfunction. Growth hormone is the most radiosensitive of the anterior pituitary hormones, followed by the gonadotropins, adrenocorticotropic hormone and thyroid-stimulating hormone. A number of factors determine both the occurrence and severity of hypothalamic-pituitary dysfunction, including: the dose of radiation received by the hypothalamic-pituitary axis (determined by a number of factors including total dose and fractionation schedule and ultimately expressed as the biological effective dose); length of time since cranial irradiation; age of the patient at the time of cranial irradiation; type of radiotherapy administered; and the different inherent radiosensitivities of the anterior pituitary hormones. These neuroendocrine abnormalities usually develop a number of years after the initial insult and, therefore, patients who have received cranial irradiation should receive annual endocrine assessments. The establishment of endocrine late-effect clinics for the survivors of childhood cancers have gone some way to addressing this problem; however, other groups of patients, particularly those receiving cranial irradiation in adult life, may not have systematic endocrine assessment.